ActivMed Practices & Research, LLC — research payments reported

By program year

4 rows

Year	Kind	Amount	Payments
2025	Research	$31,046	3
2023	Research	$8,356	1
2022	Research	$3,476	1
2021	Research	$705,977	177

Breakdown

Who paid Research payments · program years 2021–2025

Ucb SA $695,803 176 payments
Amgen Inc. $29,256 4 payments
Boehringer Ingelheim Pharmaceuticals, Inc. $23,796 2 payments

Studies the money was for Research payments · program years 2021–2025

A Multicenter, Open-Label Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis $192,346 70 payments
A Multicenter, Randomized, Double-Blind, Secukinumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis. $189,063 31 payments
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa $143,906 17 payments
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa $101,354 12 payments
A Phase 3, open-label, parallel group, multicenter, extension study evaluating the long-term treatment of bimekizumab in study participants with moderate to severe hidradenitis suppurativa $57,284 35 payments
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder $23,796 2 payments
Efficacy/Safety study of Apremilast in subjects with Mild-to-moderate Plaque Psoriasis (PSOR-022) $10,174 1 payment
US Pt Satisfaction $8,356 1 payment
A Phase 3, 24-week, Randomized, Placebo-controlled, Double-blind Study to Assess the Effect of Rocatinlimab on Vaccine Antibody Response in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER) $7,250 1 payment
A Multicenter, Open-Label, Randomized Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis $4,250 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.